CING - Cingulate Inc

CING - Cingulate Inc

https://www.cingulate.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Cingulate Posts Wider Loss in Q2

Motley Fool • 3 weeks, 5 days ago • score: 0.13

Cingulate ( NASDAQ:CING ) , a biopharmaceutical company focused initially on ADHD and anxiety, released its second-quarter results on August 19, 2025. The company's most noteworthy milestone was the submission of its NDA to the U.S.

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

GlobeNewswire • 3 weeks, 6 days ago • score: 0.12

Submitted New Drug Application ( NDA ) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in ...

Cingulate Provides Management Team Update

GlobeNewswire • 1 month ago • score: 0.25

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO ...

Cingulate Provides Management Team Update - Cingulate ( NASDAQ:CING ) , Cingulate ( NASDAQ:CINGW )

Benzinga • 1 month ago • score: 0.21

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 ( GLOBE NEWSWIRE ) -- CING The Board of Directors of Cingulate Inc. ( "Cingulate" ) announced that it has placed Chairman and Chief Executive ...

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

GlobeNewswire • 1 month, 1 week ago • score: 0.14

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients ...

Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 - Cingulate ( NASDAQ:CING ) , Cingulate ( NASDAQ:CINGW )

Benzinga • 1 month, 2 weeks ago • score: 0.06

KANSAS CITY, Kan., July 29, 2025 ( GLOBE NEWSWIRE ) -- Cingulate Inc.

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

GlobeNewswire • 4 months ago • score: 0.16

Pre-NDA Meeting for CTx-1301 ( dexmethylphenidate ) Held April 2, 2025. New Drug Application Submission Targeted for ...

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 ( buspirone ) - Cingulate ( NASDAQ:CING ) , Cingulate ( NASDAQ:CINGW )

Benzinga • 5 months ago • score: -0.04

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

GlobeNewswire • 5 months, 1 week ago • score: 0.17

NDA Submission On-Target for Mid-2025 NDA Submission On-Target for ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders. The company is headquartered in Kansas City, Kansas.

52W High

$7.00

52W Low

$3.02

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.77

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

0.03

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.36

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

3.83

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

1.88%

Institutions (25–75% balanced)

5.45%

Shares Outstanding

5,412,500

Float

5,404,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-10,680,752

EPS (TTM)

135.02

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-4.18%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.1715

Previous

-0.1920

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025